Pharmaceuticals / CROs / SMOs

Bionymity can reduce the time it takes to get drugs to market by decreasing the time it takes to recruit eligible patients for clinical trials.  By making recruitment efforts more efficient, Bionymity can decrease the time-to-market for drugs and other therapies, increasing the time that the pharmaceutical can take advantage of patent protections.

Public Health Stakeholders

Bionymity can help local, state and federal public health officials with analysis of health statistics in any community.  This analysis can be used to provide early warning for outbreaks.

Health Information Exchanges

Although the past few years have seen advances in the technology surrounding health information exchanges (HIE's), little has been done to solve the question of how to provide a business model for sustainability.  As a result, after the large capital investments to stand up such entities, most flounder and many fail.

However, Bionymity can provide HIE's with a revenue stream to offset or even cover operational costs.  By integrating Bionymity's de-identification and pseudonymization technology into the HIE infrastructure, the exchange can provide access to researchers without compromising patient privacy and reap some financial benefit as well.

In addition to direct financial benefits, integrating Bionymity's technology will create a marketable value-add for the HIE by allowing data providers to see additional revenue themselves through greater participation in clinical trials and research.